Gergely L Lukacs Selected Research

Cystic Fibrosis Transmembrane Conductance Regulator (Protein, CFTR)

1/2022	A PI3Kγ mimetic peptide triggers CFTR gating, bronchodilation, and reduced inflammation in obstructive airway diseases.
1/2020	Selective Binding of HSC70 and its Co-Chaperones to Structural Hotspots on CFTR.
1/2019	Bioactive Thymosin Alpha-1 Does Not Influence F508del-CFTR Maturation and Activity.
1/2019	Phosphorylation-dependent modulation of CFTR macromolecular signalling complex activity by cigarette smoke condensate in airway epithelia.
11/2018	Structure-guided combination therapy to potently improve the function of mutant CFTRs.
1/2018	ΔF508-CFTR Modulator Screen Based on Cell Surface Targeting of a Chimeric Nucleotide Binding Domain 1 Reporter.
8/2016	Development and characterization of synthetic antibodies binding to the cystic fibrosis conductance regulator.
10/2015	Potentiators of Defective ΔF508-CFTR Gating that Do Not Interfere with Corrector Action.
2/2015	Alcohol disrupts levels and function of the cystic fibrosis transmembrane conductance regulator to promote development of pancreatitis.
7/2014	Synergy-based small-molecule screen using a human lung epithelial cell line yields ΔF508-CFTR correctors that augment VX-809 maximal efficacy.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Gergely L Lukacs Research Topics

Disease

45	Cystic Fibrosis (Mucoviscidosis) 01/2022 - 09/2003
4	Inflammation (Inflammations) 01/2022 - 12/2006
3	Neoplasms (Cancer) 03/2022 - 10/2015
3	Asthma (Bronchial Asthma) 01/2022 - 12/2006
3	Pancreatitis 01/2016 - 02/2015
2	Respiratory Tract Diseases (Respiratory Tract Disease) 01/2022 - 11/2012
2	Pneumonia (Pneumonitis) 01/2019 - 11/2012
2	Chronic Obstructive Pulmonary Disease (COPD) 01/2016 - 11/2012
2	Renal Tubular Acidosis (Distal Renal Tubular Acidosis) 08/2014 - 02/2006
1	Brain Diseases (Brain Disorder) 03/2022
1	Leukoencephalopathies 01/2021
1	Cysts 01/2021
1	Infections 01/2019
1	Alzheimer Disease (Alzheimer's Disease) 01/2019
1	Cognitive Dysfunction 01/2019
1	Parkinson Disease (Parkinson's Disease) 01/2018
1	Neuroblastoma 01/2016
1	Neurodevelopmental Disorders 01/2016
1	Liver Diseases (Liver Disease) 01/2016
1	Christianson Type Syndromic X-Linked Mental Retardation 01/2016
1	Chronic Pancreatitis 02/2015
1	Cardiac Arrhythmias (Arrythmia) 12/2013
1	Cardiac Sudden Death (Sudden Cardiac Arrest) 12/2013
1	Long Qt Syndrome 2 12/2013
1	Inborn Genetic Diseases (Disease, Hereditary) 02/2012
1	Fibrosis (Cirrhosis) 10/2011
1	Glucocorticoid Receptor Deficiency 12/2006
1	Kidney Diseases (Kidney Disease) 02/2006
1	Diarrhea 01/2006

Drug/Important Bio-Agent (IBA)

21	Cystic Fibrosis Transmembrane Conductance Regulator (Protein, CFTR)IBA 01/2022 - 09/2003
11	Chloride Channels (Chloride Channel)IBA 08/2016 - 09/2005
8	Phenylalanine (L-Phenylalanine)FDA Link 01/2020 - 09/2005
8	NucleotidesIBA 01/2017 - 01/2005
7	AnionsIBA 01/2019 - 02/2006
6	Proteins (Proteins, Gene)FDA Link 03/2022 - 01/2011
5	ivacaftorIBA 07/2021 - 10/2015
4	Pharmaceutical PreparationsIBA 01/2012 - 01/2006
3	Ion Channels (Ion Channel)IBA 01/2022 - 12/2007
3	tezacaftorIBA 07/2021 - 01/2020
3	elexacaftorIBA 07/2021 - 01/2020
3	tezacaftor drug combination ivacaftor elexacaftorIBA 07/2021 - 01/2020
3	Membrane Proteins (Integral Membrane Proteins)IBA 01/2021 - 03/2004
2	CytokinesIBA 01/2018 - 11/2012
2	Cyclic AMP (AMP, Cyclic)IBA 07/2016 - 02/2012
2	ChloridesIBA 02/2015 - 01/2006
2	dirhodium tetraacetate (DRTA)IBA 08/2014 - 02/2006
2	Erythrocyte Anion Exchange Protein 1 (Band 3 Protein)IBA 08/2014 - 02/2006
1	Peptides (Polypeptides)IBA 01/2022
1	Adenosine (Adenocard)FDA LinkGeneric 01/2022
1	Phosphoric Diester Hydrolases (Phosphodiesterases)IBA 01/2022
1	Cyclic AMP-Dependent Protein Kinases (cAMP-Dependent Protein Kinase)IBA 01/2022
1	Drug CombinationsIBA 07/2021
1	Cell Adhesion MoleculesIBA 01/2021
1	DeuteriumIBA 01/2019
1	HydrogenIBA 01/2019
1	Caspase 6IBA 01/2019
1	DisintegrinsIBA 01/2018
1	ErbB Receptors (EGF Receptor)IBA 01/2018
1	Metalloproteases (Metalloproteinases)IBA 01/2018
1	Ligases (Synthetase)IBA 01/2018
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2018
1	UbiquitinIBA 01/2018
1	Vitamin D FDA LinkGeneric 12/2017
1	B7-H1 AntigenIBA 12/2017
1	Membrane Glycoproteins (Membrane Glycoprotein)IBA 12/2017
1	Keratin-8 (Keratin 8)IBA 01/2017
1	Phospholipids (Phosphatides)FDA LinkGeneric 01/2017
1	Indicators and Reagents (Reagents)IBA 08/2016
1	Biological ProductsIBA 08/2016
1	AntibodiesIBA 08/2016
1	Phospholipases A2 (Phospholipase A2)IBA 07/2016
1	LigandsIBA 07/2016
1	CationsIBA 01/2016
1	Bile Acids and Salts (Bile Acids)IBA 01/2016
1	Protons (Proton)IBA 01/2016
1	Amino Acids FDA Link 01/2016
1	AlkaliesIBA 01/2016
1	IntegrinsIBA 10/2015
1	Fatty Acids (Saturated Fatty Acids)IBA 02/2015
1	Ethanol (Ethyl Alcohol)IBA 02/2015
1	Ether (Diethyl Ether)IBA 12/2013
1	lumacaftorIBA 07/2013
1	Histone Deacetylases (Histone Deacetylase)IBA 01/2010
1	Epithelial Sodium ChannelsIBA 12/2007
1	GlucocorticoidsIBA 12/2006
1	Glycoproteins (Glycoprotein)IBA 02/2006
1	glycine hydrazideIBA 01/2006
1	cystic fibrosis transmembrane conductance regulator delta F508IBA 01/2006
1	AntidiarrhealsIBA 01/2006
1	Enterotoxins (Enterotoxin)IBA 01/2006
1	CurcuminIBA 04/2004

Therapy/Procedure

9	Therapeutics 01/2021 - 09/2003
1	Drug Therapy (Chemotherapy) 02/2016
1	Combination Drug Therapy (Combination Chemotherapy) 10/2015